The Desk Summary
ARCHIMED to Take Esperion Therapeutics Private in $1.1 Billion Deal
Brief
ArchiMed agreed to acquire Esperion Therapeutics for $3.16 per share in cash plus contingent milestone payments of up to $100 million, representing a total equity value of up to approximately $1.1 billion. The 58% premium to Esperion's April 30 closing price values the commercial-stage cardiometabolic biopharma at a multiple reflecting its marketed non-statin therapies NEXLETOL and NEXLIZET. The transaction, expected to close in the third quarter of 2026, is backed by debt financing from Pharmakon Advisors and is not subject to a financing condition.
ARCHIMED, a healthcare-focused investment firm, has agreed to acquire Esperion Therapeutics, a commercial-stage biopharmaceutical company, in a take-private transaction valued at up to approximately $1.1 billion.
Esperion develops and markets innovative cardiometabolic and rare/orphan disease therapies, including oral non-statin treatments for lowering LDL-C.
Under the terms, shareholders will receive $3.16 per share in cash (a 58% premium) plus contingent value rights for up to $100 million in milestone payment...
Deal details
- Buyer
- ArchiMed
- Sponsor
- ArchiMed
- Target
- Esperion Therapeutics
- Platform
- Esperion Therapeutics
- Deal type
- Platform
- Announced
- May 1, 2026
- Status
- announced